Stocks to Watch: Oracle, Acelyrin, Humacyte

By Ben Glickman

Oracle reported fiscal first-quarter growth in its cloud business slowed sequentially and compared to the year-ago quarter. Oracle's total revenue grew 9% to $12.45 billion, but was in line with analysts' estimates, according to FactSet. Shares sink 9% to $115.31 after-hours on Monday.

Acelyrin reported that one of its skin drug candidate's primary endpoint didn't meet statistical significance by week 16 of a Phase 2b/3 trial. The company, which went public in May, said it still had a strong financial position and expects its cash to fund operations through important milestones for other existing drug candidates. Shares fall 61% to $10.98 after-hours.

Humacyte said it would announce top-line data from its Phase 2/3 trial evaluating the use of implantable bioengineered human tissue in vascular trauma repair on Tuesday morning. The biotechnology company said Monday a separate study of its technology in the treatment of chronic limb-threatening ischemia yielded promising results. Shares rise 7.6% to $3.98 after-hours.

Write to Ben Glickman at [e-mail]

(END) Dow Jones Newswires

September 11, 2023 19:48 ET (23:48 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.